早期ECMO辅助复苏对难治性室颤院外心脏骤停患者的疗效:ARREST 2期随机对照试验
ARREST是一项2期、单中心、开放标签、适应性随机对照试验,纳入30例院外心脏骤停且难治性室颤的成人患者,比较早期ECMO辅助复苏与标准ACLS治疗。结果显示,ECMO组出院存活率显著高于标准ACLS组(43% vs 7%),因ECMO优效后验概率超过预设监测边界而提前终止。
要点
- 对于难治性室颤的院外心脏骤停患者,早期ECMO辅助复苏可显著提高出院存活率。
- 试验因ECMO优效后验概率超过预设边界而提前终止,需更大规模试验验证。
核心结论
- 早期ECMO辅助复苏可显著改善难治性室颤院外心脏骤停患者的出院存活率。
研究设计与样本
- 2期、单中心、开放标签、适应性、安全性与有效性随机对照试验,在美国明尼苏达大学医学中心开展。
- 纳入18-75岁院外心脏骤停且难治性室颤患者,经三次电击后未恢复自主循环,使用LUCAS装置自动心肺复苏,预计转运时间小于30分钟。
- 共30例患者随机分配至标准ACLS治疗组(n=15)或早期ECMO辅助复苏组(n=15),按意向性分析。
主要发现
- 早期ECMO组6个月累积生存率显著优于标准ACLS组。
- 未观察到非预期严重不良事件。
关键数值与推荐
- 主要结局为出院存活率,次要结局包括安全性、出院时及出院后3个月和6个月的功能评估。
- 试验因ECMO优效后验概率超过预设监测边界,在第一次预先计划的中期分析时由数据安全监测委员会建议提前终止。
临床怎么用
- 对于符合入选标准的难治性室颤院外心脏骤停患者,早期ECMO辅助复苏可作为改善存活率的策略。
- 需注意本研究为2期单中心小样本试验,结论需进一步多中心验证。
局限性
- 2期单中心小样本研究,样本量仅30例,结果需谨慎解读。
- 研究因优效提前终止,可能高估效应量。
- 开放标签设计可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Among patients with out-of-hospital cardiac arrest (OHCA) and ventricular fibrillation, more than half present with refractory ventricular fibrillation unresponsive to initial standard advanced cardiac life support (ACLS) treatment. We did the first randomised clinical trial in the USA of extracorporeal membrane oxygenation (ECMO)-facilitated resuscitation versus standard ACLS treatment in patients with OHCA and refractory ventricular fibrillation. METHODS: For this phase 2, single centre, open-label, adaptive, safety and efficacy randomised clinical trial, we included adults aged 18-75 years presenting to the University of Minnesota Medical Center (MN, USA) with OHCA and refractory ventricular fibrillation, no return of spontaneous circulation after three shocks, automated cardiopulmonary resuscitation with a Lund University Cardiac Arrest System, and estimated transfer time shorter than 30 min. Patients were randomly assigned to early ECMO-facilitated resuscitation or standard ACLS treatment on hospital arrival by use of a secure schedule generated with permuted blocks of randomly varying block sizes. Allocation concealment was achieved by use of a randomisation schedule that required scratching off an opaque layer to reveal assignment. The primary outcome was survival to hospital discharge. Secondary outcomes were safety, survival, and functional assessment at hospital discharge and at 3 months and 6 months after discharge. All analyses were done on an intention-to-treat basis. The study qualified for exception from informed consent (21 Code of Federal Regulations 50.24). The ARREST trial is registered with ClinicalTrials.gov, NCT03880565. FINDINGS: Between Aug 8, 2019, and June 14, 2020, 36 patients were assessed for inclusion. After exclusion of six patients, 30 were randomly assigned to standard ACLS treatment (n=15) or to early ECMO-facilitated resuscitation (n=15). One patient in the ECMO-facilitated resuscitation group withdrew from the study before discharge. The mean age was 59 years (range 36-73), and 25 (83%) of 30 patients were men. Survival to hospital discharge was observed in one (7%) of 15 patients (95% credible interval 1·6-30·2) in the standard ACLS treatment group versus six (43%) of 14 patients (21·3-67·7) in the early ECMO-facilitated resuscitation group (risk difference 36·2%, 3·7-59·2; posterior probability of ECMO superiority 0·9861). The study was terminated at the first preplanned interim analysis by the National Heart, Lung, and Blood Institute after unanimous recommendation from the Data Safety Monitoring Board after enrolling 30 patients because the posterior probability of ECMO superiority exceeded the prespecified monitoring boundary. Cumulative 6-month survival was significantly better in the early ECMO group than in the standard ACLS group. No unanticipated serious adverse events were observed. INTERPRETATION: Early ECMO-facilitated resuscitation for patients with OHCA and refractory ventricular fibrillation significantly improved survival to hospital discharge compared with standard ACLS treatment. FUNDING: National Heart, Lung, and Blood Institute.
引用
- Yannopoulos D, Bartos J, Raveendran G, et al. Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial. Lancet. 2020. PMID: 33197396. doi:10.1016/S0140-6736(20)32338-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。